-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers of Immune CAR-T recently investigated the efficacy and safety of ide-cel in patients with relapsed and refractory multiple myeloma.
Recently, researchers investigated the efficacy and safety of ide-cel in patients with relapsed and refractory multiple myeloma.
94 of 128 patients (73%) responded to treatment 94 of 128 patients (73%) responded to treatment 33 patients achieved minimal residual disease (MRD)-negative 33 patients achieved minimal residual disease Disease (MRD)-negative median progression-free survival was 8.
8 months.
The median progression-free survival was 8.
8 months.
More than 70% of patients with refractory and relapsed myeloma responded after receiving ide-cel treatment, of which nearly 30% of patients achieved minimal residual disease negative, and almost all patients had grade 3 or 4 adverse events, the most common being Hematological toxicity and cytokine release syndrome.
More than 70% of patients with refractory and relapsed myeloma responded after receiving ide-cel treatment, of which nearly 30% of patients achieved minimal residual disease negative, and almost all patients had grade 3 or 4 adverse events, the most common being Hematological toxicity and cytokine release syndrome.
Original source: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Leave a message here
Recently, researchers investigated the efficacy and safety of ide-cel in patients with relapsed and refractory multiple myeloma.
94 of 128 patients (73%) responded to treatment 94 of 128 patients (73%) responded to treatment 33 patients achieved minimal residual disease (MRD)-negative 33 patients achieved minimal residual disease Disease (MRD)-negative median progression-free survival was 8.
8 months.
The median progression-free survival was 8.
8 months.
More than 70% of patients with refractory and relapsed myeloma responded after receiving ide-cel treatment, of which nearly 30% of patients achieved minimal residual disease negative, and almost all patients had grade 3 or 4 adverse events, the most common being Hematological toxicity and cytokine release syndrome.
More than 70% of patients with refractory and relapsed myeloma responded after receiving ide-cel treatment, of which nearly 30% of patients achieved minimal residual disease negative, and almost all patients had grade 3 or 4 adverse events, the most common being Hematological toxicity and cytokine release syndrome.
Original source: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Leave a message here
